683 Capital Management LLC Purchases 180,420 Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL)

683 Capital Management LLC increased its stake in shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) by 14.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,400,000 shares of the company's stock after purchasing an additional 180,420 shares during the quarter. 683 Capital Management LLC owned approximately 3.42% of Vigil Neuroscience worth $2,380,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Northern Trust Corp boosted its position in shares of Vigil Neuroscience by 29.0% during the 4th quarter. Northern Trust Corp now owns 64,737 shares of the company's stock worth $110,000 after purchasing an additional 14,572 shares in the last quarter. Barclays PLC boosted its holdings in Vigil Neuroscience by 43.6% in the 4th quarter. Barclays PLC now owns 64,049 shares of the company's stock worth $109,000 after buying an additional 19,436 shares during the period. Jane Street Group LLC bought a new position in Vigil Neuroscience in the 4th quarter valued at $83,000. Geode Capital Management LLC increased its position in shares of Vigil Neuroscience by 41.9% in the third quarter. Geode Capital Management LLC now owns 226,083 shares of the company's stock worth $769,000 after purchasing an additional 66,712 shares during the last quarter. Finally, Marshall Wace LLP increased its position in shares of Vigil Neuroscience by 85.3% during the 4th quarter. Marshall Wace LLP now owns 266,895 shares of the company's stock valued at $454,000 after purchasing an additional 122,853 shares during the last quarter. 83.64% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the company. Wedbush reduced their target price on Vigil Neuroscience from $24.00 to $13.00 and set an "outperform" rating on the stock in a report on Friday, March 14th. William Blair raised shares of Vigil Neuroscience to a "strong-buy" rating in a report on Thursday, April 24th. HC Wainwright lowered their price objective on shares of Vigil Neuroscience from $17.00 to $14.00 and set a "buy" rating for the company in a research report on Friday, March 14th. Finally, Guggenheim reissued a "buy" rating on shares of Vigil Neuroscience in a research note on Friday, January 24th. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Vigil Neuroscience presently has an average rating of "Buy" and an average target price of $16.25.

Vigil Neuroscience Stock Performance

VIGL stock opened at $2.56 on Friday. The firm has a market cap of $125.75 million, a price-to-earnings ratio of -1.24 and a beta of 1.94. The firm has a 50-day simple moving average of $1.92 and a two-hundred day simple moving average of $2.37. Vigil Neuroscience, Inc. has a one year low of $1.31 and a one year high of $6.06.

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last posted its quarterly earnings data on Thursday, March 13th. The company reported ($0.57) earnings per share for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.08). As a group, equities analysts predict that Vigil Neuroscience, Inc. will post -2.07 earnings per share for the current fiscal year.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.